Skip Nav Destination
Hydroxyurea for SCA in Africa: no malaria harm
Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2
Issue Archive
December 14 2017
Table of Contents
INSIDE BLOOD COMMENTARIES
INSIDE BLOOD COMMENTARY
Hydroxyurea for SCA in Africa: no malaria harm
Clinical Trials & Observations
PLENARY PAPER
CLINICAL TRIALS AND OBSERVATIONS
Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia
Clinical Trials & Observations
Robert O. Opoka,Christopher M. Ndugwa,Teresa S. Latham,Adam Lane,Heather A. Hume,Phillip Kasirye,James S. Hodges,Russell E. Ware,Chandy C. John
REVIEW ARTICLE
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Clinical Trials & Observations
Hervé Avet-Loiseau,Nizar J. Bahlis,Wee-Joo Chng,Tamas Masszi,Luisa Viterbo,Ludek Pour,Peter Ganly,Antonio Palumbo,Michele Cavo,Christian Langer,Andrzej Pluta,Arnon Nagler,Shaji Kumar,Dina Ben-Yehuda,S. Vincent Rajkumar,Jesus San-Miguel,Deborah Berg,Jianchang Lin,Helgi van de Velde,Dixie-Lee Esseltine,Alessandra di Bacco,Philippe Moreau,Paul G. Richardson
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia
Brenton G. Mar,S. Haihua Chu,Josephine D. Kahn,Andrei V. Krivtsov,Richard Koche,Cecilia A. Castellano,Jacob L. Kotlier,Rebecca L. Zon,Marie E. McConkey,Jonathan Chabon,Ryan Chappell,Peter V. Grauman,James J. Hsieh,Scott A. Armstrong,Benjamin L. Ebert
MYELOID NEOPLASIA
Gene expression and risk of leukemic transformation in myelodysplasia
Yusuke Shiozawa,Luca Malcovati,Anna Gallì,Andrea Pellagatti,Mohsen Karimi,Aiko Sato-Otsubo,Yusuke Sato,Hiromichi Suzuki,Tetsuichi Yoshizato,Kenichi Yoshida,Yuichi Shiraishi,Kenichi Chiba,Hideki Makishima,Jacqueline Boultwood,Eva Hellström-Lindberg,Satoru Miyano,Mario Cazzola,Seishi Ogawa
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
Cytoprotective activated protein C averts Nlrp3 inflammasome–induced ischemia-reperfusion injury via mTORC1 inhibition
Sumra Nazir,Ihsan Gadi,Moh’d Mohanad Al-Dabet,Ahmed Elwakiel,Shrey Kohli,Sanchita Ghosh,Jayakumar Manoharan,Satish Ranjan,Fabian Bock,Ruediger C. Braun-Dullaeus,Charles T. Esmon,Tobias B. Huber,Eric Camerer,Chris Dockendorff,John H. Griffin,Berend Isermann,Khurrum Shahzad
TRANSPLANTATION
Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2
Clinical Trials & Observations
Hasan Hashem,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Ashish R. Kumar,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Ingo Müller,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Florian Babor,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Robbert Bredius,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Jignesh Dalal,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Amy P. Hsu,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Steven M. Holland,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Dennis D. Hickstein,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Stephen Jolles,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Robert Krance,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Ghadir Sasa,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Mervi Taskinen,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Minna Koskenvuo,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Janna Saarela,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Joris van Montfrans,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Keith Wilson,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Barbara Bosch,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Leen Moens,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Michael Hershfield,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Isabelle Meyts,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation
BLOOD WORK
-
Cover Image
Cover Image
A 5-μm-thick left ventricle cross-cryosection obtained 24 hours after reperfusion and stained by triphenyltetrazolium chloride solution (TTC). The pale region that fails to stain (TTC-negative region) represents nonviable infarcted myocardium. Constitutively active Nlrp3A350V abolishes the protective effect of activated protein C in myocardial ischemia reperfusion injury. See the article by Nazir et al on page 2664.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals